Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DNA
stocks logo

DNA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
37.69M
-14.04%
-1.800
-10%
44.27M
-8.37%
-1.130
-32.74%
46.75M
-5.76%
-0.950
-13.64%
Estimates Revision
The market is revising Downward the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by -1.46% over the past three months. During the same period, the stock price has changed by -17.40%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.46%
In Past 3 Month
Stock Price
Go Down
down Image
-17.40%
In Past 3 Month
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
3 Sell
Moderate Sell
Current: 9.210
sliders
Low
9.00
Averages
11.50
High
14.00
Current: 9.210
sliders
Low
9.00
Averages
11.50
High
14.00
BTIG
Sell
maintain
$6 -> $9
2025-08-25
Reason
BTIG
Price Target
$6 -> $9
2025-08-25
maintain
Sell
Reason
BTIG raised the firm's price target on Ginkgo Bioworks to $9 from $6 but keeps a Sell rating on the shares. The firm cites the company's "significant' Q2 topline beat as it was able to take out costs faster than expected, the analyst tells investors in a research note. BTIG notes however that while Ginkgo reiterated that reaching adjusted EBITDA breakeven by 2026-end is its number one goal, it will be a "close one" if Ginkgo can hit its EBITDA positivity target given the lack of visibility on the growth outlook of the business in 2026.
TD Cowen
Buy
upgrade
$12 -> $16
2025-08-08
Reason
TD Cowen
Price Target
$12 -> $16
2025-08-08
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ginkgo Bioworks to $16 from $12 and keeps a Buy rating on the shares. The firm said Cell Engineering drove the Q2 beat despite softer biosecurity revenues.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA.N) is -1.94, compared to its 5-year average forward P/E of -15.29. For a more detailed relative valuation and DCF analysis to assess Ginkgo Bioworks Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.29
Current PE
-1.94
Overvalued PE
14.15
Undervalued PE
-44.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-18.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.67
Undervalued EV/EBITDA
-52.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.83
Current PS
0.00
Overvalued PS
27.39
Undervalued PS
-1.73
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DNA News & Events

Events Timeline

(ET)
2025-11-06
16:29:57
Ginkgo Bioworks Announces Q3 Earnings Per Share of $1.45, Exceeding Consensus Estimate of $1.24
select
2025-11-03 (ET)
2025-11-03
08:08:16
Ginkgo Bioworks Secures $22.2 Million Contract via BARDA BioMaP Consortium
select
2025-10-31 (ET)
2025-10-31
08:05:31
Ginkgo Bioworks expands collaboration with Bayer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-03PRnewswire
STRM.BIO Secures $8.4M ARPA-H Contract to Advance Cell Therapy
  • Funding Support: STRM.BIO has secured an $8.4 million contract from ARPA-H to support the development of its proprietary megakaryocyte-derived extracellular vesicle delivery platform, significantly enhancing the company's competitive edge in the biotechnology sector.
  • Technological Innovation: This platform represents a novel cell-derived delivery modality capable of overcoming key barriers faced by current viral and synthetic delivery systems, which is expected to unlock new therapeutic opportunities in gene and cell therapy to address unmet medical needs.
  • Partnership Collaboration: STRM.BIO will lead the project in collaboration with Ginkgo Bioworks, the University of British Columbia, and Advanced Bioprocess Services, leveraging their respective expertise to develop in vivo CAR-T therapeutics, thereby enhancing the project's technical strength and market potential.
  • Strategic Implications: This funding not only accelerates the development of STRM.BIO's MV platform and genetic medicines pipeline but also advances the broader field of cell and gene therapy, showcasing the company's leadership in innovative non-viral delivery technologies.
[object Object]
Preview
7.5
11-18PRnewswire
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health

  • Partnership Announcement: Ginkgo Bioworks has partnered with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year initiative called MIGHTY, aimed at developing new oral health treatments using advanced microbial technologies.

  • Technology Utilization: Ginkgo will employ its EncapS technology for ultra-high-throughput screening to discover phage-based therapies targeting specific bacteria in the oral microbiome, enhancing the potential for effective health interventions.

  • Expert Insights: Key figures from both Ginkgo and the University of Illinois highlighted the significance of the EncapS technology in accelerating phage therapy research, emphasizing its potential to revolutionize treatment approaches for bacterial infections in oral health.

  • Commitment to Innovation: This collaboration reflects Ginkgo's dedication to advancing scientific research and its role as a leader in phage isolation and screening, aiming to foster partnerships across academia and industry for innovative biological solutions.

[object Object]
Preview
9.5
11-08Benzinga
Ginkgo Bioworks Shares Drop After Q3 Estimates Fall Short, Maintains FY2025 Forecast Below Market Expectations

  • Financial Performance: Ginkgo Bioworks reported a loss of $1.45 per share for Q3, exceeding estimates of $1.24, and a significant increase in losses compared to the previous year. Quarterly sales were $38.8 million, slightly below the $38.9 million estimate and down 56.39% from $89 million last year.

  • Revenue Breakdown: Total revenue for the third quarter was $39 million, a 56% decline from the previous year, largely due to a $45 million non-cash revenue from a terminated deal. Cell Engineering revenue also fell 61% to $29 million, but excluding the non-cash revenue, the decline was minimal.

  • Adjusted EBITDA: The company's adjusted EBITDA was negative $56 million, worsening from negative $20 million in the same quarter last year, primarily due to the release of non-cash deferred revenue in the prior year.

  • Stock Performance: Following the financial results, Ginkgo Bioworks shares dropped 21.95% to $8.82, while the company maintained its fiscal year 2025 revenue outlook between $167 million and $187 million, aligning closely with analyst expectations of $177.1 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) stock price today?

The current price of DNA is 9.21 USD — it has increased 2.22 % in the last trading day.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s business?

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

arrow icon

What is the price predicton of DNA Stock?

Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s revenue for the last quarter?

Ginkgo Bioworks Holdings Inc revenue for the last quarter amounts to 38.84M USD, decreased -56.39 % YoY.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s earnings per share (EPS) for the last quarter?

Ginkgo Bioworks Holdings Inc. EPS for the last quarter amounts to -1.45 USD, increased 34.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ginkgo Bioworks Holdings Inc (DNA)'s fundamentals?

The market is revising Downward the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by -1.46% over the past three months. During the same period, the stock price has changed by -17.40%.
arrow icon

How many employees does Ginkgo Bioworks Holdings Inc (DNA). have?

Ginkgo Bioworks Holdings Inc (DNA) has 834 emplpoyees as of December 05 2025.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) market cap?

Today DNA has the market capitalization of 559.25M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free